preserves the cancer tissue architecture, including the vasculature and immune system, accurately reflecting the cancer growth found in the body.

Curesponse’s cutting edge functional platform will match the correct drug to the patient's cancer, improving survival and saving unnecessary medical interventions. The company is harnessing the technology to create a personalized cancer diagnostic assay that can be used to determine the drug response for a specific individual's tumor type.